Elevation Oncology is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data, leading the ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its ...

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients ...

Prague headquartered clinical-stage firm SOTIO Biotech, which is owned by the Czech Republic's PPF Group, today announced it ...

Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology ...

The bispecific antibody candidates were identified by SOTIO’s research team and will now be developed under SOTIO’s license and option agreement with Synaffix, which enables SOTIO to combine ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

PRAGUE, Czech Republic & AMSTERDAM, The Netherlands I March 13, 2025 I SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, ...

Three-program alliance with Synaffix reflects SOTIO's commitment to further broaden and advance innovative ADC pipeline SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF ...

PRAGUE & AMSTERDAM–(BUSINESS WIRE)–SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option agreement with Synaffix B.V. (“Synaffix”), ...